The spike (S) glycoprotein of coronaviruses is essential for binding of the virus to the host cell at the beginning of the infection process. The target protein is also a major immunogen and a possible target for entry inhibitors.
The SARS-CoV-2 spike (S) protein is a large type I transmembrane protein composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) responsible for binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2). Several mutants of the spike protein are known. A new SARS-CoV-2 lineage called B.1.617, exhibits 13 mutations. Compared to the previously circulating variants, the mutations L452R and T478K of the SARS-CoV-2 Spike S1 (RBD) may cause a stronger affinity of the spike protein to hACE2 and also conferring an increasing ability to evade the hosts’ immune system.
|
SDS-PAGE/Coll. Coomassie
|
Histogram of marked lane in gel picture
|
|
|
|
The table below lists publications that mention this catalog protein. To sort the table, click on the first row.
Have you cited this product in a publication? Let us know so we can reference it here.
| Citation Date |
Citation Title |
Citation Authors |
Citation Abstract |
Citation DOI |
| 13 June 2023 |
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells |
Alexandra Kegler, Laura Drewitz, Claudia Arndt, Cansu Daglar, Liliana Rodrigues Loureiro, et al. |
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence... read more
|
https://doi.org/10.3389/fimmu.2023.1204543 |
|
|
|
|
|
